Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;91(2):205.
doi: 10.1007/s12098-023-04817-0. Epub 2023 Sep 30.

Optimizing the Long-Term Therapy with Eculizumab (ECU) for Atypical Hemolytic Uremic Syndrome (aHUS)

Luisa Santangelo  1 , Giuseppe Stefano Netti  2 , Sebastiano Mazza  1 , Francesca Zito  1 , Valeria Catalano  3 , Marida Martino  1 , Diletta Domenica Torres  1 , Vincenza Carbone  1 , Elena Ranieri  3 , Mario Giordano  3
Affiliations

Optimizing the Long-Term Therapy with Eculizumab (ECU) for Atypical Hemolytic Uremic Syndrome (aHUS)

Luisa Santangelo et al. Indian J Pediatr. 2024 Feb.
No abstract available

PubMed Disclaimer

References

    1. Fakhouri F, Fila M, Provôt F, et al. Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Clin J Am Soc Nephrol. 2017;12:50–9. - DOI - PubMed
    1. Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15–39. - DOI - PubMed
    1. Ariceta G. Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)- a question to be addressed in a scientific way. Pediatr Nephrol. 2019;34:943–9. - DOI - PubMed
    1. Gurevich E, Landau D. Pharmacological management of atypical hemolytic uremic syndrome in pediatric patients: current and future. Paediatr Drugs. 2023;25:193–202. - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources